The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has unveiled plans to evaluate the safety and efficacy of futibatinib (TAS-120), a potent inhibitor of the fibroblast growth factor receptor (FGFR).

The oncology research programme of NCCN provides innovation and knowledge discovery that can improve the lives of cancer patients. It also supports preclinical, clinical research and quality improvement projects in the field of oncology at member institutions of NCCN.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Under the project, NCCN will evaluate pre-clinical, translational and clinical trials using futibatinib as a monotherapy and in biologically relevant combination regimens for malignancies identified with FGFR 1-4 aberrations.

This research project will be the first NCCN programme to assess the efficacy of an FGFR inhibitor.

NCCN chief medical officer Wui-Jin Koh said: “We still have a lot to learn about FGFR signalling and how to optimally target this receptor as a component of cancer therapy. We look forward to the potential new discoveries that may come from these investigations.”

The research project is backed by $2m in funding from Japanese pharmaceutical firm Taiho Oncology.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Taiho Oncology senior vice-president and chief medical officer Martin J Birkhofer said: “We are proud to support NCCN ORP research to better understand the optimal role of futibatinib in treating malignancies with FGFR 1-4 aberrations.

“Every day, we are learning more and more about futibatinib, and this research will expand our knowledge of how this investigational compound works, with the goal of being able to better target its use in those who may see the greatest benefit from it.”

NCCN noted that the first phase of this research project will involve the RFP creation, which is expected to be distributed in the coming months.

The awarded projects under the ORP will be revealed after the review of submitted proposals.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact